[TENAGA] QoQ Annualized Quarter Result on 31-Dec-2019 [#4]

Announcement Date
28-Feb-2020
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
31-Dec-2019 [#4]
Profit Trend
QoQ- -12.36%
YoY- 21.63%
View:
Show?
Annualized Quarter Result
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
Revenue 44,868,933 45,090,600 46,618,000 50,939,700 51,683,466 52,241,600 52,979,200 -10.45%
PBT 4,458,400 4,122,200 4,065,600 5,477,700 6,270,533 6,312,800 8,294,400 -33.81%
Tax -1,238,933 -1,296,800 -1,118,800 -1,032,700 -1,122,666 -1,010,200 -2,209,600 -31.93%
NP 3,219,466 2,825,400 2,946,800 4,445,000 5,147,866 5,302,600 6,084,800 -34.50%
-
NP to SH 3,174,400 2,742,400 2,871,600 4,529,200 5,167,866 5,346,000 6,227,200 -36.10%
-
Tax Rate 27.79% 31.46% 27.52% 18.85% 17.90% 16.00% 26.64% -
Total Cost 41,649,466 42,265,200 43,671,200 46,494,700 46,535,600 46,939,000 46,894,400 -7.58%
-
Net Worth 53,792,160 54,574,606 54,587,875 57,981,810 57,382,980 58,498,181 57,696,331 -4.55%
Dividend
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
Div 1,670,393 2,503,343 - 5,686,888 2,274,755 3,412,133 - -
Div Payout % 52.62% 91.28% - 125.56% 44.02% 63.83% - -
Equity
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
Net Worth 53,792,160 54,574,606 54,587,875 57,981,810 57,382,980 58,498,181 57,696,331 -4.55%
NOSH 5,704,653 5,704,596 5,686,888 5,686,888 5,686,888 5,686,888 5,686,888 0.20%
Ratio Analysis
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
NP Margin 7.18% 6.27% 6.32% 8.73% 9.96% 10.15% 11.49% -
ROE 5.90% 5.03% 5.26% 7.81% 9.01% 9.14% 10.79% -
Per Share
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
RPS 787.93 792.53 819.75 895.74 908.82 918.63 931.60 -10.53%
EPS 55.75 48.20 50.48 79.64 90.88 94.00 109.52 -36.16%
DPS 29.33 44.00 0.00 100.00 40.00 60.00 0.00 -
NAPS 9.4463 9.5923 9.5989 10.1957 10.0904 10.2865 10.1455 -4.63%
Adjusted Per Share Value based on latest NOSH - 5,686,888
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
RPS 775.30 779.13 805.52 880.19 893.04 902.69 915.43 -10.45%
EPS 54.85 47.39 49.62 78.26 89.30 92.37 107.60 -36.10%
DPS 28.86 43.26 0.00 98.26 39.31 58.96 0.00 -
NAPS 9.2948 9.43 9.4323 10.0187 9.9153 10.108 9.9694 -4.55%
Price Multiplier on Financial Quarter End Date
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
Date 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 28/06/19 29/03/19 -
Price 10.50 11.62 12.02 13.26 13.64 13.84 12.66 -
P/RPS 1.33 1.47 1.47 1.48 1.50 1.51 1.36 -1.47%
P/EPS 18.84 24.11 23.80 16.65 15.01 14.72 11.56 38.36%
EY 5.31 4.15 4.20 6.01 6.66 6.79 8.65 -27.70%
DY 2.79 3.79 0.00 7.54 2.93 4.34 0.00 -
P/NAPS 1.11 1.21 1.25 1.30 1.35 1.35 1.25 -7.59%
Price Multiplier on Announcement Date
30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 CAGR
Date 26/11/20 28/08/20 10/06/20 28/02/20 27/11/19 30/08/19 28/05/19 -
Price 10.96 10.86 11.92 12.10 13.56 13.96 11.66 -
P/RPS 1.39 1.37 1.45 1.35 1.49 1.52 1.25 7.31%
P/EPS 19.66 22.53 23.61 15.19 14.92 14.85 10.65 50.31%
EY 5.09 4.44 4.24 6.58 6.70 6.73 9.39 -33.44%
DY 2.68 4.05 0.00 8.26 2.95 4.30 0.00 -
P/NAPS 1.16 1.13 1.24 1.19 1.34 1.36 1.15 0.57%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment